Research Highlights

Since its inception, the Vancouver Prostate Centre’s research activities have led to valuable new insights, treatments, and intellectual property:

  • We were instrumental in establishing the use of Intermittent Androgen Ablation Therapy as a standard treatment modality for prostate cancer
  • In response to the global COVID-19 pandemic, Dr. Cherkasov's team utilized their novel AI-based platform, Deep Docking, to work on finding the top candidate compounds for effective antiviral therapeutics; their work towards a cure is ongoing
  • Dr. Jefferies has a COVID-19 research project to test and deliver a candidate COVID-19 vaccine and other clinical tools to address current societal needs; if these vaccines are successful, they will be produced safely and efficiently and then mass distributed, at a reasonable cost, and with acceptable shelf-life
  • In 2015, the Centre developed a potential new therapeutic that is designed to outsmart cancer and inhibit tumour growth by disabling the androgen receptor where it binds to a specific part of the DNA that is not prone to mutation, opening the possibility of designing drugs that could be effective for a long time
    • The drug candidate was developed using computer-aided drug design (CADD), a technology that evaluates a database of millions of different molecules to identify a handful which may work well as possible treatments
  • My Precision Oncology Program (MyPOP), made possible by infrastructural investment from the Canadian Foundation for Innovation and a generous donation by a private donor, allows for the routine linking of genomic sequencing data with real-time clinical decision making
  • Our annual knowledge output averages 120 peer-reviewed publications and 150 presentations at conferences
  • Since 2008, our Centre has been awarded over $125 million in peer-reviewed research grants from regional, national and international agencies
  • Since 2008 we have initiated 138 new Clinical Trials enrolling 2,886 patients
  • We have a strong record of recruitment of senior staff and faculty promotions
  • The Centre currently had 37 post-doctoral fellows, 35 Ph.D. students and 13 Masters students
  • Since 2008 we have negotiated 56 new contract research agreements with pharmaceutical and biotech companies including Pfizer, Takeda, AstraZeneca, Bayer and Janssen
  • Intellectual Property Activities since 2008 include
    •  294 patent filed/issued
    •  9 Licensing Agreements of IP with Industry (8 drug, 1 biomarker)
      • Our 2015 licensing to Roche was UBC's largest out-licensing deal to date
  • Discoveries at our Centre have led to the creation of several biotech companies, including OncoGeneX (now Achieve Life Sciences) and Aquinox

 

Page updated March 27, 2020

A World Class Centre

The Vancouver Prostate Centre (VPC) has a track record of success that has earned it a reputation as one of the world’s most respected cancer facilities. It is a National Centre of Excellence and a designated Centre of Excellence for Commercialization and Research.

Events

VPC Terry Fox team 2016

Terry Fox Run - September 20, 2020

The 40th annual Terry Fox Run takes place on Sunday September 20 across Canada, as a virtual event.  Please consider donating to or joining our TFRI-VPC team as we raise funds to enable The Terry Fox Foundation & The Terry Fox Research Institute to continue their support of innovative and progressive cancer research programs

Employment

Work at the Vancouver Prostate Centre

Thursday, September 24, 2020

Drs. Gleave, Lack and Wang awarded CIHR Project Grants

Tuesday, September 8, 2020

MSFHR 2020 Awardees: Drs. Hach, Gentile, Massah

Thursday, June 25, 2020

Drs. Cherkasov and Jean receive CIHR grant to find new antiviral drugs to treat COVID-19